Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

29 Jan 2020

Abstract excerpt

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6...

Topics

Join the communities discussing this publication.

Chronic Myeloid Leukemia Treatments
Histone Deacetylase Inhibitors Research
Peptidase Inhibition and Analysis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32013157
DOI: 10.3390/cancers12020318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?PMID 32013157Read ↗

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative DiseaseSemantic proximity Read ↗

Histone deacetylase 6 in cancerSemantic proximity Read ↗

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cellsSemantic proximity Read ↗

Histone Deacetylase 6 in Health and DiseaseSemantic proximity Read ↗

The therapeutic hope for HDAC6 inhibitors in malignancy and chronic diseaseSemantic proximity Read ↗

Role of HDACs in normal and malignant hematopoiesisSemantic proximity Read ↗

Targeting Histone Deacetylases 6 in Dual-Target Therapy of CancerSemantic proximity Read ↗

HDAC6: Tumor Progression and BeyondSemantic proximity Read ↗

Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human DiseasesSemantic proximity Read ↗

Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal CancerSemantic proximity Read ↗

HDAC6 and Ovarian CancerSemantic proximity Read ↗

Inhibition of HDAC6 activity in kidney diseases: a new perspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.